A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh

Fahima Chowdhury, Afroza Akter, Taufiqur Rahman Bhuiyan, Imam Tauheed, Samuel Teshome, Arijit Sil, Ju Yeon Park, Yun Chon, Jannatul Ferdous, Salima Raiyan Basher, Faez Ahmed, Mahbubul Karim, Mohammad Mainul Ahasan, Masudur Rahman Mia, Mir Mohammad Ibna Masud, Abdul Wahab Khan, Masum Billah, Zebun Nahar, Imran Khan, Allen G. RossDeok Ryun Kim, Md Muktadir Rahman Ashik, Laura Digilio, Julia Lynch, Jean Louis Excler, John D. Clemens, Firdausi Qadri

    Research output: Contribution to journalArticlepeer-review

    2 Downloads (Pure)

    Abstract

    Bangladesh remains cholera endemic with biannual seasonal peaks causing epidemics. At least 300,000 severe cases and over 4,500 deaths occur each year. The available oral cholera vaccines have not yet been adopted for cholera control in Bangladesh due to insufficient number of doses available for endemic control. With a public private partnership, icddr,b initiated a collaboration between vaccine manufacturers in Bangladesh and abroad. A locally manufactured Oral Cholera Vaccine (OCV) named Cholvax became available for testing in Bangladesh. We evaluated the safety and immunogenicity of this locally produced Cholvax (Incepta Vaccine Ltd) inexpensive OCV comparatively to Shanchol (Shantha Biotechnics-Sanofi Pasteur) which is licensed in several countries. We conducted a randomized non-inferiority clinical trial of bivalent, killed oral whole-cell cholera vaccine Cholvax vs. Shanchol in the cholera-endemic area of Mirpur, Dhaka, among three different age cohorts (1–5, 6–17 and 18–45 years) between April 2016 and April 2017. Two vaccine doses were given at 14 days apart to 2,052 healthy participants. No vaccine-related serious adverse events were reported. There were no significant differences in the frequency of solicited (7.31% vs. 6.73%) and unsolicited (1.46% vs. 1.07%) adverse events reported between the Cholvax and Shanchol groups. Vibriocidal antibody responses among the overall population for O1 Ogawa (81% vs. 77%) and O1 Inaba (83% vs. 84%) serotypes showed that Cholvax was non-inferior to Shanchol, with the non-inferiority margin of −10%. For O1 Inaba, GMT was 462.60 (Test group), 450.84 (Comparator group) with GMR 1.02(95% CI: 0.92, 1.13). For O1 Ogawa, GMT was 419.64 (Test group), 387.22 (Comparator group) with GMR 1.12 (95% CI: 1.02, 1.23). Cholvax was safe and non-inferior to Shanchol in terms of immunogenicity in the different age groups. These results support public use of Cholvax to contribute for reduction of the cholera burden in Bangladesh. ClinicalTrials.gov number: NCT027425581.

    Original languageEnglish
    Pages (from-to)640-649
    Number of pages10
    JournalVaccine
    Volume40
    Issue number4
    DOIs
    Publication statusPublished - 28 Jan 2022

    Fingerprint

    Dive into the research topics of 'A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh'. Together they form a unique fingerprint.

    Cite this